Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout flare

FDA Update: New Drug Approvals, New & Expanded Indications, & More

Susan Bernstein  |  March 12, 2020

ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingapremilastCertolizumab PegolFebuxostatixekizumabJAK inhibitorsnintedanibrituximabU.S. Food and Drug Administration (FDA)upadacitinib

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

Susan Bernstein  |  February 12, 2020

Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual MeetingBiologicsFDAU.S. Food and Drug Administration (FDA)

Bending, Not Breaking

Philip Seo, MD, MHS  |  August 16, 2019

“And of course, I am not telling you to do it. That would be illegal.” As a general rule, I try not to instruct my patients to break the law. My business model depends on repeat customers, so placing a patient at risk of getting arrested—even if that risk is remote—doesn’t seem like a good…

Filed under:EthicsOpinionRheuminationsSpeak Out Rheum Tagged with:Canadian drugsdrug costs

Genes, Not Diet, Main Determinant of Urate Levels

Anne Harding  |  October 17, 2018

NEW YORK (Reuters Health)—Heredity plays a substantially larger role than diet in determining serum urate levels, according to new findings in BMJ. Nearly 25% of the variation in serum urate is attributable to common genetic variants, while dietary pattern explained less than 1%, Dr. Tanya J. Major of the University of Otago in Dunedin, New…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutheredityserum urate levelsTanya J. Major

How to Manage Pain & Treatment in Elderly Patients

Richard Quinn  |  August 25, 2017

Elderly patients have unique requirements with regard to treatment for pain, rheumatic disease and other ailments. Collaboration between rheumatologists, geriatricians and primary care physicians is essential to avoid unnecessary interventions and improve care for this patient population…

Filed under:Practice Support Tagged with:elderlygeriatricgeriatricspatient careTreatment

Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient

Arthritis & Rheumatology  |  December 29, 2016

Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:AllopurinolArthritis & RheumatologyGoutlesinuradResearchUric acid

Biosimilar for Infliximab Launched in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 1, 2015

Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsDrugsFDAinfliximabKaufmanrheumatologySafety

Hospitalists Gain Insight on Signs, Symptoms of Infection Among Inpatients on Biologic Drugs

Richard Quinn  |  June 6, 2014

Rheumatologist at Society of Hospital Medicine conference provides treatment recommendations for hospital patients with rheumatic disease

Filed under:Practice Support Tagged with:biologic drugsInfectioninpatientrheumatology

Clinical Applications of Dual-Energy Computed Tomography for Rheumatology

Nicola Dalbeth, MBChB, MD, FRACP  |  June 1, 2014

Advanced imaging technique allows physicians to detect deposition of monosodium urate crystals not apparent in physical exams and better diagnose gout

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:crystal arthritisDECTGoutimagingrheumatologistTechnologyUltrasound

Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

Kimberly Retzlaff  |  April 2, 2014

Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:AC&RAmerican College of Rheumatology (ACR)anti-inflammatoryCardiovascular diseaseColchicinecrystal arthritisGoutimagingOsteoarthritispatient carerheumatology symposium

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences